Forest Laboratories, Inc. Announces Publication In Lancet Of Pivotal Phase III Hypertension Trial Of The Fixed-Dose Combination Of Nebivolol/Valsartan

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. In the study, the combination of nebivolol and valsartan met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at 8 weeks in patients with hypertension.

Help employers find you! Check out all the jobs and post your resume.